Rocket Pharmaceuticals, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. Rocket is a clinical-stage gene-therapy company with no approved products or product-sales revenue. Its programs target rare diseases using lentiviral and AAV platforms.
Financial and operating metrics
| Metric | Q3 2022 / September 30, 2022 | Comparable period / change |
|---|---|---|
| Revenue | $0 | $0 in Q3 2021 |
| Research and development expense | $43.4 million | Up from $39.6 million in Q3 2021 |
| General and administrative expense | $15.1 million | Up from $10.0 million in Q3 2021 |
| Total operating expenses | $58.5 million | Up from $49.6 million in Q3 2021 |
| Net loss | $57.8 million; $0.87 per share | Q3 2021: $50.1 million; $0.79 per share |
| Cash, cash equivalents and investments | $306.5 million | Cash and equivalents: $196.7 million; investments: $109.9 million |
| Operating cash flow | $(122.1) million for nine months | $(90.2) million for nine months of 2021 |
| Cash, cash equivalents and restricted cash | $198.0 million at period end | Declined $36.0 million since year-end 2021 |
| Liabilities and lease obligations | $50.0 million total liabilities, including $21.0 million finance lease liability | No material conventional borrowing balance disclosed |
Margins: Not meaningful because the company had no revenue. For the first nine months, operating expenses were $155.3 million and net loss was $155.1 million, versus $122.9 million and $124.8 million, respectively, in 2021.
Material changes and financing
- For the first nine months, R&D expense increased $23.1 million, primarily from manufacturing and development costs, laboratory supplies, personnel and direct materials. G&A expense rose $9.3 million, including increased headcount, commercial preparation and legal costs.
- Net loss for the first nine months widened to $155.1 million from $124.8 million. Higher operating costs were partly offset by improved net other income and lower interest expense.
- The company raised $46.6 million net through its at-the-market program through September 30, issuing approximately 3.3 million shares. On October 6, it completed a follow-on offering of 7.82 million shares for $108.2 million net proceeds.
- Management said available resources, including the subsequent offering proceeds, were expected to fund operating and capital expenditure needs into the second half of 2024. This is a company estimate, not a guarantee.
Programs, outlook and risks
- Danon disease (RP-A501): The company reported preliminary Phase 1 safety and activity observations in small adult and pediatric cohorts. It focused on the lower dose after a high-dose patient experienced complement-mediated thrombotic microangiopathy and later received a heart transplant. The filing said Phase 2 planning was expected to begin in Q4 2022, subject to results and regulatory discussions.
- Fanconi anemia (RP-L102): Management said the Phase 2 primary endpoint had been achieved and anticipated further data in Q4 2022 and a BLA filing in the second half of 2023. In October 2022, the company disclosed that a treated patient developed T-cell lymphoblastic lymphoma; analysis indicated negligible vector markings in the tumor, and the patient was reported in complete response.
- Severe LAD-I (RP-L201): All nine treated patients were reported alive and clinically stable at the cited data cut-off. The company anticipated a BLA filing in the first half of 2023.
- Pyruvate kinase deficiency (RP-L301): Two adult patients had reported sustained improvements in hemoglobin and transfusion independence; pediatric enrollment was ongoing. Management expected additional data in the first half of 2023 and Phase 2 initiation in 2023.
- Rocket had agreed to acquire Renovacor, with closing expected by Q1 2023, subject to customary conditions, including shareholder and regulatory approvals. The initial exchange ratio was 0.1676, subject to adjustment. The company recorded approximately $1.3 million in related costs during Q3.
- Key risks include clinical and regulatory uncertainty, manufacturing execution, patient enrollment, need for future capital and potential dilution. Management also cited capital-market volatility and risks that the Renovacor transaction may be delayed, fail to close or not deliver expected benefits. The filing noted an ongoing New York City audit of biotechnology tax credits for 2018–2020.
Most important facts for investors to verify
- Actual cash use, financing proceeds, share dilution and whether the stated runway remains adequate as development spending changes.
- Subsequent clinical data and FDA/other regulator feedback, especially Danon dose and safety plans, and timing and evidentiary requirements for RP-L102 and RP-L201 filings.
- Whether the small, early-stage clinical results are sustained in larger or longer-followed patient groups, including safety findings and the RP-L102 lymphoma follow-up.
- Renovacor closing status, final exchange-ratio adjustments, integration costs and any evidence of anticipated benefits.
- Whether manufacturing capacity and supply are sufficient for planned pivotal studies and potential commercialization.